AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
Latest, Q2 2026
3,632
Period ended Jun 30, 2026
Change on a year earlier
+11.7%
3,253 in Q2 2025
History
58 quarters
Since Q1 2012
Sources
49
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Selling, general and administrative expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 3,632 | +11.7% | Form 10-Q (filed 2026-08-03) ↗ |
| Q1 2026 | Mar 31, 2026 | 3,578 | +8.7% | Form 10-Q (filed 2026-05-08) ↗ |
| Q4 2025 | Dec 31, 2025 | 3,895 | +1.0% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2025 | Sep 30, 2025 | 3,569 | -15.1% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 3,253 | -3.7% | Form 10-Q (filed 2025-08-04) ↗ |
| Q1 2025 | Mar 31, 2025 | 3,293 | -0.7% | Form 10-Q (filed 2025-05-09) ↗ |
| Q4 2024 | Dec 31, 2024 | 3,855 | +20.7% | Form 10-K (filed 2025-02-14) ↗ |
| Q3 2024 | Sep 30, 2024 | 4,205 | +24.7% | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 3,377 | +3.3% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 3,315 | +9.1% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2023 | Dec 31, 2023 | 3,193 | -6.6% | Form 10-K (filed 2024-02-20) ↗ |
| Q3 2023 | Sep 30, 2023 | 3,372 | +2.1% | Form 10-Q (filed 2023-11-06) ↗ |
| Q2 2023 | Jun 30, 2023 | 3,268 | -39.6% | Form 10-Q (filed 2023-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 3,039 | -2.8% | Form 10-Q (filed 2023-05-05) ↗ |
| Q4 2022 | Dec 31, 2022 | 3,417 | +4.8% | Form 10-K (filed 2023-02-17) ↗ |
| Q3 2022 | Sep 30, 2022 | 3,304 | +7.2% | Form 10-Q (filed 2022-11-04) ↗ |
| Q2 2022 | Jun 30, 2022 | 5,412 | +71.0% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 3,127 | +10.0% | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2021 | Dec 31, 2021 | 3,260 | +0.9% | Form 10-K (filed 2022-02-18) ↗ |
| Q3 2021 | Sep 30, 2021 | 3,083 | +8.3% | Form 10-Q (filed 2021-11-02) ↗ |
| Q2 2021 | Jun 30, 2021 | 3,164 | -10.3% | Form 10-Q (filed 2021-08-02) ↗ |
| Q1 2021 | Mar 31, 2021 | 2,842 | +67.7% | Form 10-Q (filed 2021-05-07) ↗ |
| Q4 2020 | Dec 31, 2020 | 3,231 | +65.6% | Form 10-K (filed 2021-02-19) ↗ |
| Q3 2020 | Sep 30, 2020 | 2,846 | +71.8% | Form 10-Q (filed 2020-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 3,527 | +113.2% | Form 10-Q (filed 2020-08-04) ↗ |
| Q1 2020 | Mar 31, 2020 | 1,695 | +0.9% | Form 10-Q (filed 2020-05-08) ↗ |
| Q4 2019 | Dec 31, 2019 | 1,951 | +1.1% | Form 10-K (filed 2020-02-21) ↗ |
| Q3 2019 | Sep 30, 2019 | 1,657 | -13.7% | Form 10-Q (filed 2019-11-06) ↗ |
| Q2 2019 | Jun 30, 2019 | 1,654 | -6.0% | Form 10-Q (filed 2019-08-05) ↗ |
| Q1 2019 | Mar 31, 2019 | 1,680 | -6.2% | Form 10-Q (filed 2019-05-03) ↗ |
| Q4 2018 | Dec 31, 2018 | 1,929 | -1.4% | Form 10-K (filed 2019-02-27) ↗ |
| Q3 2018 | Sep 30, 2018 | 1,919 | +31.7% | Form 10-Q (filed 2018-11-07) ↗ |
| Q2 2018 | Jun 30, 2018 | 1,760 | +16.6% | Form 10-Q (filed 2018-08-07) ↗ |
| Q1 2018 | Mar 31, 2018 | 1,791 | +30.4% | Form 10-Q (filed 2018-05-04) ↗ |
| Q4 2017 | Dec 31, 2017 | 1,956 | +16.5% | Form 10-K (filed 2019-02-27) ↗ |
| Q3 2017 | Sep 30, 2017 | 1,457 | +5.5% | Form 10-Q (filed 2018-11-07) ↗ |
| Q2 2017 | Jun 30, 2017 | 1,509 | +2.9% | Form 10-Q (filed 2018-08-07) ↗ |
| Q1 2017 | Mar 31, 2017 | 1,373 | +1.3% | Form 10-Q (filed 2018-05-04) ↗ |
| Q4 2016 | Dec 31, 2016 | 1,679 | -3.3% | Form 10-K (filed 2019-02-27) ↗ |
| Q3 2016 | Sep 30, 2016 | 1,381 | -6.3% | Form 10-Q (filed 2016-11-07) ↗ |
| Q2 2016 | Jun 30, 2016 | 1,466 | -13.9% | Form 10-Q (filed 2016-08-05) ↗ |
| Q1 2016 | Mar 31, 2016 | 1,355 | -8.0% | Form 10-Q (filed 2016-05-06) ↗ |
| Q4 2015 | Dec 31, 2015 | 1,737 | -48.0% | Form 10-K (filed 2016-02-19) ↗ |
| Q3 2015 | Sep 30, 2015 | 1,474 | -7.6% | Form 10-Q (filed 2015-11-06) ↗ |
| Q2 2015 | Jun 30, 2015 | 1,703 | +17.6% | Form 10-Q (filed 2015-08-07) ↗ |
| Q1 2015 | Mar 31, 2015 | 1,473 | +9.9% | Form 10-Q (filed 2015-05-08) ↗ |
| Q4 2014 | Dec 31, 2014 | 3,341 | +130.7% | Form 10-K (filed 2015-02-20) ↗ |
| Q3 2014 | Sep 30, 2014 | 1,595 | +26.5% | Form 10-Q (filed 2014-11-07) ↗ |
| Q2 2014 | Jun 30, 2014 | 1,448 | +3.0% | Form 10-Q (filed 2014-08-07) ↗ |
| Q1 2014 | Mar 31, 2014 | 1,340 | +8.3% | Form 10-Q (filed 2014-05-09) ↗ |
| Q4 2013 | Dec 31, 2013 | 1,448 | +2.6% | Form 10-K (filed 2014-02-21) ↗ |
| Q3 2013 | Sep 30, 2013 | 1,261 | +16.2% | Form 10-Q (filed 2013-11-12) ↗ |
| Q2 2013 | Jun 30, 2013 | 1,406 | +12.8% | Form 10-Q (filed 2013-08-09) ↗ |
| Q1 2013 | Mar 31, 2013 | 1,237 | -0.8% | Form 10-Q (filed 2013-05-08) ↗ |
| Q4 2012 | Dec 31, 2012 | 1,411 | – | Form 10-K (filed 2014-02-21) ↗ |
| Q3 2012 | Sep 30, 2012 | 1,085 | – | Form 10-Q (filed 2013-11-12) ↗ |
| Q2 2012 | Jun 30, 2012 | 1,246 | – | Form 10-Q (filed 2013-08-09) ↗ |
| Q1 2012 | Mar 31, 2012 | 1,247 | – | Form 10-Q (filed 2013-05-08) ↗ |
Cite this data
StockData. (2026). AbbVie Selling, general and administrative expense ($M) ($M), quarterly Q1 2012–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/fs_sga
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.